$9bn valuation, zero revenue from its core tech—guess it

The Valuation That Defied Physics

Theranos reached a $9 billion valuation in 2014 by promising to run hundreds of blood tests from a single finger prick, using proprietary devices called Edison and MiniLab. The pitch was irresistible: cheaper, faster, less painful than traditional venipuncture. Walgreens signed a partnership to install Theranos Wellness Centers in forty stores across Arizona and California. Safeway spent $350 million remodeling clinics in preparation for a nationwide rollout. Yet throughout this period, the company never published peer-reviewed validation studies, never disclosed failure rates, and never demonstrated that its devices could reliably perform the tests it advertised. Investors poured in $700 million total, drawn by founder Elizabeth Holmes's story—a Stanford dropout in a black turtleneck, echoing Steve Jobs, claiming she could democratize health care. The valuation rested entirely on the premise that the technology worked. It didn't.

What the Devices Actually Did

By 2015, Theranos was running most of its patient tests on standard commercial analyzers purchased from Siemens, not on its own Edison machines. When the Edison devices were used, employees diluted blood samples to stretch the tiny finger-prick volumes, a practice that introduced error and invalidated results. A Wall Street Journal investigation revealed that the company was performing only fifteen of the 240-plus tests it advertised on its proprietary devices; the rest went through conventional equipment. Internal emails showed engineers flagging wildly inconsistent results—quality-control failures that would never pass regulatory scrutiny. Theranos nonetheless reported patient results to doctors, who made clinical decisions based on faulty data. The Centers for Medicare and Medicaid Services later found deficiencies so severe that they posed "immediate jeopardy to patient health and safety," leading to sanctions that banned Holmes from owning or operating a lab for two years.

The People Who Believed

Holmes assembled a board that read like a Cold War reunion: George Shultz, Henry Kissinger, William Perry, James Mattis, Richard Kovacevich. Not one had a background in diagnostics, laboratory medicine, or life sciences. Shultz's grandson, Tyler Shultz, worked at Theranos as a lab associate and raised concerns internally about test quality; he was threatened with legal action and estranged from his grandfather for months. Whistleblower Erika Cheung, another lab worker, documented protocol violations and eventually contacted regulators. Both faced retaliation. Meanwhile, Walgreens continued opening wellness centers even as its own consultant, a Johns Hopkins pathologist, warned that Theranos's data looked wrong. Safeway CEO Steve Burd championed the partnership so zealously that he missed the signs; the grocery chain never recovered its $350 million investment. Patients received incorrect cholesterol, thyroid, and pregnancy results, some leading to unnecessary medical interventions.

Why the Story Still Lands

The Theranos collapse triggered a reckoning over Silicon Valley's "fake it till you make it" ethos. Regulatory oversight of lab-developed tests remains fragmented; the FDA does not pre-approve most of them, leaving a gap that Theranos exploited. Holmes was convicted in January 2022 on four counts of wire fraud, sentenced to eleven years in federal prison, and ordered to pay $452 million in restitution to investors including Rupert Murdoch and the Walton family. Her former COO and romantic partner, Ramesh "Sunny" Balwani, received a thirteen-year sentence. The case underscored that hardware fraud in health care carries consequences that software startups rarely face—people's lives depend on the results. Venture capitalists now claim to scrutinize life-sciences pitches more carefully, though skepticism remains whether the lesson stuck. The Theranos story endures because it married the two most American obsessions: the charismatic founder myth and the catastrophic failure that followed.